FDA Inspection 1168571 — Oklahoma Blood Institute Southwest
The FDA completed an inspection of Oklahoma Blood Institute Southwest on Apr 20, 2022 in Lawton, OK. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 20, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Lawton, OK (United States)